Nutrition focus and immune support: why USANA Proglucamune stays on many supplement lists

USANA’s Proglucamune supplement targets everyday immune support with a blend of mushroom-derived beta-glucans and zinc. We look at what the capsules contain, how they are positioned, and where they fit into the broader USANA portfolio.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 11:16 AM ET. Details in the imprint.

USANA’s Proglucamune immune-support supplement sits in a crowded nutrition aisle, but the product continues to attract attention with its combination of mushroom-derived beta-glucans, a unique baker’s yeast strain and added zinc. The once-daily tablet is marketed for adults who want daily support for “immune resiliency” rather than a quick fix for acute illness, a positioning that aligns with USANA’s broader emphasis on long-term wellness. According to the company, Proglucamune is formulated for year-round use and is designed to complement a multivitamin rather than replace it.

What Proglucamune is designed to do and what is in the formula

At its core, Proglucamune is a dietary supplement that combines beta-glucans from reishi and shiitake mushrooms with a proprietary baker’s yeast extract (referred to as PGG-Glucan) plus zinc and a small amount of selenium to support normal immune function. USANA states that each daily serving delivers 250 mg of the PGG-Glucan yeast extract and 200 mg of a mushroom blend alongside 5 mg of zinc, in tablets that are intended to be taken with food once a day. The product is sold in bottles of 56 tablets, reflecting a 28-day supply for adults taking the recommended two-tablet daily dose, and is positioned as gluten-free and suitable for vegetarians on the official product page. USANA’s product description for Proglucamune details the full ingredient list, tablet count and usage guidance.

The key marketing claim from USANA is that the specific blend of beta-glucans is intended to help maintain the normal function of immune cells under everyday stress, such as lack of sleep, intense exercise or travel, rather than acting as a stimulant. To support this positioning, the company points to internal and external studies on yeast-derived beta-1,3/1,6-glucans and mushroom extracts, although the Proglucamune finished product itself is not registered as a drug and does not carry disease-treatment claims. The supplement sits in USANA’s immune-support category alongside products like Vitamin D and Poly C, but it is distinguished by its use of mushroom and yeast ingredients instead of focusing purely on vitamins and minerals.

From a consumer perspective, Proglucamune targets adults who are generally healthy but may feel that job pressure, parenting, frequent travel or sports training routinely push their immune system. The tablets are relatively small compared to some high-dose multivitamins, which can matter for user adherence. USANA underlines that Proglucamune is tested in-house and through selected third-party laboratories as part of the company’s quality program, a notable point for investors and consumers who follow regulatory headlines about supplement quality control and label accuracy.

Pricing for Proglucamune reflects USANA’s positioning as a premium direct-selling brand. In the US, the product is typically listed at around $49.95 for a 28-day supply at the consumer price, with preferred customers and associates able to access discounted pricing through USANA’s membership model. That places it at a premium compared with many mass-market immune blends but closer to other specialized mushroom and beta-glucan supplements in the practitioner and network-marketing segments. USANA distributes Proglucamune primarily via its network of independent associates and its own online store, and the product is registered for sale in multiple markets outside the US, including parts of Asia and Europe, subject to local regulatory requirements. A recent overview by industry outlet NutraIngredients noted that mushroom-based immune supplements have been one of the faster-growing subcategories in the wider immune-health segment over the past few years, with brands like USANA leaning into this trend.

Regulatory-wise, Proglucamune is classified as a dietary supplement in the United States, meaning it is regulated under the Dietary Supplement Health and Education Act (DSHEA) framework and does not require pre-market approval by the US Food and Drug Administration (FDA). USANA must, however, follow current good manufacturing practices (cGMP) and ensure that claims stay within the allowed “structure/function” language, such as “supports normal immune function.” The FDA provides general guidance on how supplement makers should label products and avoid disease-treatment claims, and USANA’s labeling and online descriptions fit squarely into that structure/function category rather than making drug-style promises. The FDA’s dietary supplement information outlines these requirements for immune-support products.

Within USANA’s broader portfolio, Proglucamune plays a supporting role alongside its flagship multivitamin CellSentials and its range of targeted supplements for bone health, heart health and metabolism. The product offers the company another way to cross-sell into its existing customer base, especially in markets where immune support remains a priority after the COVID-19 pandemic and during seasonal flu periods. For USANA, which derives the bulk of its revenue from nutritionals and personal-care products sold through a direct-selling model, immune-support items like Proglucamune can help stabilize revenue by encouraging daily use and automatic monthly reorders.

USANA Health Sciences, the manufacturer behind Proglucamune, is headquartered in Salt Lake City, Utah and generates a significant portion of its sales in Asia-Pacific markets such as China, South Korea and Southeast Asia, even though products like Proglucamune are also sold in North America and Europe. The company is publicly listed on the New York Stock Exchange under the ticker USNA, with the security identified by ISIN US91232N1081, and it reports its quarterly and annual results via its investor-relations website, where management regularly discusses performance in core product categories, including immune-support supplements such as Proglucamune. USANA’s investor-relations section highlights how its immune-support line, including Proglucamune, contributes to overall nutrition category revenue.

USANA Proglucamune quick facts

• Product: Proglucamune
• Manufacturer: USANA Health Sciences Inc.
• Category: Immune-support dietary supplement
• Launch date: Not formally disclosed; available in the US for several years
• MSRP / Price: About $49.95 for 56 tablets (28-day supply) in the US
• Availability: USANA online store and independent USANA associates in the US and selected international markets
• Target audience: Adults seeking daily immune-support supplementation
• Key differentiator / USP: Combination of mushroom-derived beta-glucans and proprietary yeast extract with zinc in a once-daily, vegetarian tablet

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.